# A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

> **NCT04867616** · PHASE2 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 466 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** Bepranemab

## Key facts

- **NCT ID:** NCT04867616
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-09
- **Primary completion:** 2024-05-24
- **Final completion:** 2025-08-01
- **Target enrollment:** 466 (ACTUAL)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04867616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04867616, "A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04867616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*